WS
MBRX icon

Wedbush Securities’s Moleculin Biotech MBRX Stock Holding History

Wedbush Securities’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4
Closed -$19K – 857
2017
Q2 		$19K Hold
4
– – ﹤0.01% 825
2017
Q1 		$12K Buy
+4
New +$14K ﹤0.01% 831

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wedbush Securities's MBRX Position: Q3 2017 in Review

Wedbush Securities sold out of Moleculin Biotech (MBRX) in Q3 2017, closing a stake of 4 shares — an estimated $19K sold.

Wedbush Securities first reported a position in MBRX in Q1 2017 and held it in 2 quarters. The position peaked at $19K in Q2 2017. 10 funds tracked by Wall St. Rank hold MBRX as of Q3 2017.

  • Wedbush Securities reported no remaining Moleculin Biotech position as of Q3 2017 after selling out during the quarter.
  • Wedbush Securities sold 4 Moleculin Biotech shares in Q3 2017, an estimated $19K.
  • Wedbush Securities first reported a position in Moleculin Biotech in Q1 2017 and held it in 2 quarters.
  • Wedbush Securities's Moleculin Biotech position peaked at $19K in Q2 2017.
  • 10 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2017.

Based on Wedbush Securities's 13F filing for Q3 2017, filed 31 Oct 2017.